QuidelOrtho Corporation subsidiary Ortho Clinical Diagnostics Trading (China) Co. Ltd. is forming a joint venture with Runda Medical Technology Co. Ltd. subsidiary Shanghai Medconn Biotechnology Co. Ltd. to develop and manufacture assays in China for QuidelOrtho’s VITROS platform.
 
“Our partnership with Runda Medical will help expand our already-compelling menu of VITROS assays abroad as well as in the Chinese market, an important, fast-growing region for us,” QuidelOrtho President/CEO Douglas Bryant stated. “We’re happy with our long-standing partnership and believe that this joint venture will translate into a faster time to market and more compelling menu for VITROS assays in support of our growth strategy in China and beyond.”
 
QuidelOrtho develops IVD reagent products that meet the needs of the Chinese market with a significant installed base of VITROS immunodiagnostic analyzers, including but not limited to VITROS 3600 and 5600 instruments and the VITROS Automation System that connects these instruments, and has a position in quick turnaround STAT labs across China. Runda Medical is an in-vitro diagnostics distributor in China and has developed its own family of instruments and assays. The JV will leverage both parties’ know-how in a range of incremental assays to broaden the VITROS test menu and gain efficiencies from local manufacturing at Runda Medical’s Shanghai facility. Both companies will contribute personnel and expertise to the joint venture and will share in the profits of the jointly developed products.
 
“Our longstanding collaboration with Runda Medical has enabled us to become a leader in commercial execution in the China market over the past 20 years,” said Iris Lin, Head of Greater China at QuidelOrtho, who will continue in this role and also manage the the joint venture. “We value our partnership with Runda Medical and with their expanded immunoassay menu, we look forward to rapidly launching important assays to the market with accurate, efficient results.”
 
“Runda Medical has maintained a close and positive working relationship with Ortho for nearly two decades. This partnership is another in-depth strategic cooperation in the field of in vitro diagnostic product research, development and production. Both parties make full use of complementary resources and commit to providing medical laboratories with higher quality in vitro diagnostic platforms and reagents and providing effective support for the diagnosis and treatment of clinical diseases,” Runda Medical General Manager Hui Liu stated.
 
Following a successful assay pilot program, both companies expect to begin developing a broader set of assays in early 2023 in parallel with building out the JV organization in the Shanghai and Beijing areas.
 
QuidelOrtho Corporation develops and manufactures diagnostic testing technologies. Ranked among the world’s largest in-vitro diagnostics providers with more than 120 years of collective experience, the company combines expertise in immunoassay and molecular testing with a global footprint in clinical labs and transfusion medicine.
 
Runda Medical provides product distribution and comprehensive services in the in-vitro diagnostic industry in China. Runda Medical has experience in supply chain and technical services for IVD products and is committed to providing all types of medical laboratories with integrated medical laboratory services, including various medical solutions, a full range of IVD products and professional technical support. Runda Medical has built a business ecosystem consisting of integrated laboratory service platforms, IVD product research, development and production, medical informatization, third-party laboratory testing services and other services. Currently, Runda Medical has more than 50 holding subsidiaries, providing integrated laboratory services to more than 4,000 public medical institutions in China.